22 Boston Wharf Road
Floor 7
Boston, MA 02210
United States
929 274 7510
https://www.akaritx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 9
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Ms. Wendy F. DiCicco CPA | Interim Chief Financial Officer | 540.34k | N/A | 1967 |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Akari Therapeutics, Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.